Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. Management's webcast is scheduled for April 13, 2026 at 3:45 PM EDT.
According to the company, the presentation webcast will be available April 13 with a replay accessible for approximately 90 days on Milestone's News & Events page. Investors seeking meetings should contact their Needham representative.
Positive
- None.
Negative
- None.
News Market Reaction – MIST
On the day this news was published, MIST gained 5.92%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.8% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $12M to the company's valuation, bringing the market cap to $211.21M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MIST is up 10.14% while 2 tracked peers (e.g., GLSI, KYTX) also appear in momentum scans, each up about 2.2%. Sector data notes that 2 peer stocks are moving up together, suggesting broader biotech strength alongside today’s conference headline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Inducement option grants | Neutral | +5.3% | New hires received 123,000 stock options under the 2021 Inducement Plan. |
| Mar 31 | Formulary access news | Positive | +17.8% | CARDAMYST added to Express Scripts commercial national formularies, broadening access. |
| Mar 20 | Earnings and launch | Positive | -20.0% | Reported 2025 results with CARDAMYST FDA approval and U.S. launch details. |
| Mar 16 | Clinical data update | Positive | -0.9% | ACC.26 data showed minimal blood pressure impact and low hypotension/syncope rates. |
| Mar 12 | Earnings date set | Neutral | +2.3% | Announced timing and access details for Q4 and full-year 2025 results call. |
News tied to commercial progress or access (like formulary wins) has coincided with strong upside, while larger fundamental updates, including financials and clinical data, have sometimes seen negative or muted reactions.
Over the last month, MIST has moved through several milestones. On Mar 12, it set an earnings date, followed by ACC.26 safety data for CARDAMYST on Mar 16. Full-year 2025 results and launch details on Mar 20 coincided with a sharp selloff, whereas Express Scripts formulary inclusion on Mar 31 produced a strong positive move. Recent inducement option grants on Apr 2 saw modest gains. Today’s conference appearance fits into this pattern of frequent, varied news flow.
Market Pulse Summary
The stock moved +5.9% in the session following this news. A strong positive reaction aligns with recent periods where commercial- or visibility-related news supported upside, as seen after formulary access updates. However, MIST still traded below its 200-day MA of $1.88, and prior fundamental disclosures have sometimes been followed by sharp drawdowns. With peers also moving higher, part of the 10.14% gain may reflect broader sector momentum rather than this conference appearance alone.
AI-generated analysis. Not financial advice.
MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference to take place April 13 - 16, 2026.
A webcast of the presentation will be available on April 13th at 3:45 PM EDT. The webcast will be available to watch here and there will be a replay for approximately 90 days on the News & Events section of Milestone's website www.milestonepharma.com.
If you are interested in meeting with the Milestone team during the conference, please contact your Needham representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
